Myomo, Inc. (MYO) Stock Analysis | Price, Returns, Financials & Key Metrics

Price Point

High/Low

1Day

52 Week

Valuation

Technical

Day's Volume

CASH

1.39 M

Shareholding (Mar 2025)

FII

10.76%

Held by 24 FIIs

DII

82.93%

Held by 8 DIIs

Promoter

0.00%

How big is Myomo, Inc.?

22-Jun-2025

As of Jun 18, Myomo, Inc. has a market capitalization of 98.94 million, with net sales of 38.63 million and a net profit of -5.82 million over the last four quarters. Shareholder's funds total 24.71 million, and total assets are valued at 42.24 million.

What does Myomo, Inc. do?

22-Jun-2025

Myomo, Inc. is a U.S. medical device company that develops myoelectric orthotics for individuals with neurological disorders. As of March 2025, it reported net sales of $10 million and a net loss of $3 million, with a market cap of approximately $98.94 million.

Who are in the management team of Myomo, Inc.?

22-Jun-2025

As of March 2022, the management team of Myomo, Inc. includes Steve Kelly as Founder, Chairman, President, and COO, and Paul Gudonis as CEO and Director.

Is Myomo, Inc. overvalued or undervalued?

20-Sep-2025

As of November 6, 2017, Myomo, Inc. is considered overvalued and risky due to its high Price to Book Value of 4.94, negative EV to EBIT and EV to EBITDA ratios, a return on equity of -26.80%, and significant underperformance with a year-to-date return of -86.96% compared to the S&P 500's 12.22%.

Is Myomo, Inc. technically bullish or bearish?

20-Sep-2025

As of May 8, 2025, Myomo, Inc. is in a bearish trend, indicated by negative signals from multiple technical indicators, including MACD, RSI, and moving averages, and has underperformed the S&P 500 with a year-to-date return of -86.96%.

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

MarketsMojo — Loved in India, Now Global

The power of Mojo is now in 29 countries. Explore global equities with the same cutting-edge features you love.Unlock 29 Markets

Dashboard

Unrated Stock - No Analysis Available

Mojo Parameters

Stock DNA

Industry

Retailing

Market cap

USD 38 Million (Micro Cap)

P/E

NA (Loss Making)

Industry P/E

Dividend Yield

0.00%

Debt Equity

-0.63

Return on Equity

-52.93%

Price to Book

2.13

Revenue and Profits:

Net Sales:

10 Million

(Quarterly Results - Jun 2025)

Net Profit:

-5 Million

Total Returns

Total Returns (Price + Dividend)

TimePeriod

Price Return

Dividend Return

Total Return

3 Months

0.99%

6 Months

-64.58%

1 Year

-80.93%

2 Years

-74.94%

3 Years

59.25%

4 Years

-86.31%

5 Years

-85.0%

Myomo, Inc. for the last several years.

Risk Adjusted Returns v/s

News & Corporate Actions

News

Is Myomo, Inc. technically bullish or bearish?

As of 8 May 2025, the technical trend for Myomo, Inc. has changed from mildly bearish to bearish. The current stance is bearish with a strong indication from multiple indicators. The MACD is bearish on both weekly and monthly time frames, and the RSI shows a bearish signal on the monthly. Moving averages are bearish on the daily, and the Bollinger Bands are bearish on both weekly and monthly periods. Additionally, the KST and Dow Theory indicate bearish trends as well. In terms of performance, Myomo has significantly underperformed the S&P 500 across all periods, with a year-to-date return of -86.96% compared to the S&P 500's 12.22%. Overall, the technical indicators strongly support a bearish outlook for the stock....

Is Myomo, Inc. overvalued or undervalued?

As of 6 November 2017, Myomo, Inc. moved from a grade of does not qualify to risky, indicating a significant downgrade in its valuation outlook. The company appears to be overvalued given its high Price to Book Value of 4.94 and negative EV to EBIT and EV to EBITDA ratios of -14.81 and -18.39, respectively. Additionally, the return on equity (ROE) stands at -26.80%, further highlighting the company's struggles. In comparison to its peers, Myomo's valuation ratios are concerning, particularly when looking at its peer with a P/E ratio of -4.0264 and EV to EBITDA of -3.378. The stark contrast in performance is evident as Myomo's stock has significantly underperformed against the S&P 500, with a year-to-date return of -86.96% compared to the S&P 500's 12.22%. This underperformance reinforces the notion that Myomo, Inc. is currently overvalued....

No announcement available

Corporate Actions

No corporate action available

Key Factors

Quality key factors

Factor

Value

Sales Growth (5y)

59.17%

EBIT Growth (5y)

3.76%

EBIT to Interest (avg)

-9.20

Debt to EBITDA (avg)

Negative Net Debt

Net Debt to Equity (avg)

-0.96

Sales to Capital Employed (avg)

1.84

Tax Ratio

7.79%

Dividend Payout Ratio

Pledged Shares

Institutional Holding

63.52%

ROCE (avg)

ROE (avg)

Valuation key factors

Factor

Value

P/E Ratio

NA (Loss Making)

Industry P/E

Price to Book Value

4.94

EV to EBIT

-14.81

EV to EBITDA

-18.39

EV to Capital Employed

86.46

EV to Sales

2.24

PEG Ratio

Dividend Yield

ROCE (Latest)

-583.82%

ROE (Latest)

-26.80%

Technicals key factors

Indicator

Weekly

Monthly

MACD

Mildly Bullish

Bearish

RSI

No Signal

Bollinger Bands

Mildly Bearish

Bearish

Moving Averages

Bearish (Daily)

KST

Mildly Bullish

Mildly Bearish

Dow Theory

Mildly Bearish

OBV

No Trend

Mildly Bullish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Shareholding

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Majority shareholders

Foreign Institutions

Domestic Funds

Held in 10 Schemes (6.31%)

Foreign Institutions

Held by 24 Foreign Institutions (10.76%)

Strategic Entities with highest holding

Highest Public shareholder

Financial

[
  {
    "link": "quarterly",
    "btn_text": "All Quarterly Results",
    "header": "Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -1.02% vs -19.01% in Mar 2025",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "QoQ Growth in quarter ended Jun 2025 is -31.43% vs -1,066.67% in Mar 2025",
        "dir": 1
      }
    ],
    "table": {
      "header": [
        "Jun'25",
        "Mar'25",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "9.70",
          "val2": "9.80",
          "chgp": "-1.02%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-4.20",
          "val2": "-3.10",
          "chgp": "-35.48%",
          "chgp_class": "negative"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-4.60",
          "val2": "-3.50",
          "chgp": "-31.43%",
          "chgp_class": "negative"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-475.60%",
          "val2": "-358.00%",
          "chgp": "-11.76%",
          "chgp_class": "negative"
        }
      ]
    }
  },
  {
    "link": "annual",
    "btn_text": "All Annual Results",
    "header": "Annual Results Snapshot (Consolidated) - Dec'24",
    "rhs": [
      {
        "prefix": "Net Sales ",
        "suffix": "YoY Growth in year ended Dec 2024 is 69.79% vs 23.08% in Dec 2023",
        "dir": 1
      },
      {
        "prefix": "Consolidated Net Profit ",
        "suffix": "YoY Growth in year ended Dec 2024 is 23.46% vs 24.30% in Dec 2023",
        "dir": -1
      }
    ],
    "table": {
      "header": [
        "Dec'24",
        "Dec'23",
        "Change(%)"
      ],
      "body": [
        {
          "field": "Net Sales",
          "val1": "32.60",
          "val2": "19.20",
          "chgp": "69.79%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit (PBDIT) excl Other Income",
          "val1": "-5.40",
          "val2": "-7.70",
          "chgp": "29.87%",
          "chgp_class": "positive"
        },
        {
          "field": "Interest",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Exceptional Items",
          "val1": "0.00",
          "val2": "0.00",
          "chgp": "",
          "chgp_class": "neutral"
        },
        {
          "field": "Consolidate Net Profit",
          "val1": "-6.20",
          "val2": "-8.10",
          "chgp": "23.46%",
          "chgp_class": "positive"
        },
        {
          "field": "Operating Profit Margin (Excl OI)",
          "val1": "-190.70%",
          "val2": "-427.80%",
          "chgp": "23.71%",
          "chgp_class": "positive"
        }
      ]
    }
  }
]

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Jun'25

Mar'25

Change(%)

Net Sales

9.70

9.80

-1.02%

Operating Profit (PBDIT) excl Other Income

-4.20

-3.10

-35.48%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-4.60

-3.50

-31.43%

Operating Profit Margin (Excl OI)

-475.60%

-358.00%

-11.76%

USD in Million.

Compare with Peers

Net Sales

QoQ Growth in quarter ended Jun 2025 is -1.02% vs -19.01% in Mar 2025

Consolidated Net Profit

QoQ Growth in quarter ended Jun 2025 is -31.43% vs -1,066.67% in Mar 2025

All Quarterly Results

Annual Results Snapshot (Consolidated) - Dec'24

Dec'24

Dec'23

Change(%)

Net Sales

32.60

19.20

69.79%

Operating Profit (PBDIT) excl Other Income

-5.40

-7.70

29.87%

Interest

0.00

Exceptional Items

0.00

Consolidate Net Profit

-6.20

-8.10

23.46%

Operating Profit Margin (Excl OI)

-190.70%

-427.80%

23.71%

USD in Million.

Compare with Peers

Net Sales

YoY Growth in year ended Dec 2024 is 69.79% vs 23.08% in Dec 2023

Consolidated Net Profit

YoY Growth in year ended Dec 2024 is 23.46% vs 24.30% in Dec 2023

All Annual Results

Company CV

About Myomo, Inc.

Myomo, Inc.

Retailing

Myomo, Inc. is a United States-based medical device company specializing in myoelectric orthotics for people with neurological disorders. The Company’s products help to restore function in individuals with neuromuscular conditions, such as brachial plexus injury, spinal cord injury, multiple sclerosis and stroke. Its MyoPro myoelectric limb orthosis is a powered brace that supports a weakened and deformed arm for functional use. The MyoPro is an elbow/wrist/Hand orthosis, which supports the arm and helps to bend and straighten the arm at the elbow. The brace provides assistive function for joint motion that enables a user to self-initiate and control movements of a partially paralyzed arm using their own muscle signals. When the user tries to bend their arm, sensors in the brace detect the weak muscle signal, which activates the motor to amplify their weak muscle signal to help bend and move their arm. The brace uses non-invasive skin sensors.

Company Coordinates

Company Details

ONE BROADWAY, 14TH FLOOR , CAMBRIDGE MA : 02142

Tel: 1 617 9969058

http://myomo.com/

Registrar Details

Myomo, Inc.

1Day

52 Week

CASH

FII

DII

Promoter

How big is Myomo, Inc.?

Watch in Real-Time

What does Myomo, Inc. do?

Who are in the management team of Myomo, Inc.?

Is Myomo, Inc. overvalued or undervalued?

Is Myomo, Inc. technically bullish or bearish?

MarketsMojo — Loved in India, Now Global

Dashboard

Mojo Parameters

Stock DNA

Total Returns (Price + Dividend)

Risk Adjusted Returns v/s

News

Is Myomo, Inc. technically bullish or bearish?

Is Myomo, Inc. overvalued or undervalued?

Announcements

Corporate Actions

Quality key factors

Valuation key factors

Technicals key factors

Shareholding Snapshot : Mar 2025

Shareholding Compare (%holding)

Quarterly Results Snapshot (Consolidated) - Jun'25 - QoQ

Annual Results Snapshot (Consolidated) - Dec'24

About Myomo, Inc.

Company Coordinates